Lifeward Ltd.LFWDNASDAQ

Overview Intelligence Charts News Fundamentals

Latest News

globenewswire.com

Lifeward Announces Collaboration With Shirley Ryan AbilityLab to Expand Access for the ReWalk Personal Exoskeleton

Clinic d ays offered at Shirley Ryan AbilityLab, the #1 ranked rehabilitation hospital for 35 consecutive years , with the goal of a ccelerat ing p ersonal e xoskeleton a doption S treamlined pathway from evaluation to real-world use of ReWalk for people living with spinal cord injury (SCI) HUDSON, Mass. and CHICAGO, March 02, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

globenewswire.com

Lifeward to Acquire Powered Upper Body Exoskeleton with AI Capabilities Designed to Restore Function to Stroke Survivors

IP and technology acquisition is expected to be highly accretive and to advance Lifeward's position as a diversified biomedical innovation company Will Expand Lifeward's portfolio beyond lower-limb solutions, creating a differentiated, whole-body neuro-rehabilitation portfoli o Will Strengthen long-term strategic networks with neuro-rehabilitation prescribers, rehabilitation networks, and payers HUDSON, Mass. and YOKNEAM ILLIT, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

globenewswire.com

Lifeward Announces Reverse Share Split

Reverse split initiated as Lifeward enters strategic partnership agreement and repositions as MedTech innovation company Reverse split initiated as Lifeward enters strategic partnership agreement and repositions as MedTech innovation company

globenewswire.com

Lifeward's ReWalk™ Personal Exoskeleton Now Covered by Aetna, Coverage Expands to Include Three of the Largest Medicare Advantage Insurers

Aetna joins Humana and United Healthcare in providing Medicare Advantage coverage for beneficiaries who meet medical necessity criteria for the ReWalk Personal Exoskeleton

globenewswire.com

Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company

Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotech upside potential Up to $47 million strategic investment from Oramed and another investor is intended to provide Lifeward cash runway to profitability and diversify its portfolio across MedTech and BioTech Lifeward acquires Oramed's clinical-stage Protein Oral Delivery (POD™) technology adding exposure to a large, long-term Biotech market opportunity POD™ targets the $600+ billion injectable drugs market, including ORMD-0801, which has the potential to become the world's first commercialized oral insulin medicine MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

prnewswire.com

Oramed and Lifeward Announce Strategic Transaction

Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder Oramed will transfer POD™ platform to Lifeward while retaining management of clinical program Oramed will receive 49.9% beneficial ownership interest in Lifeward, a revenue-generating medical robotics company, including warrants Mark Grant, Lifeward CEO, with 25+ years experience in the diabetes sector at Medtronic and Bristol Myers Squibb, to lead combined platforms In addition, strategic investment by Oramed designed to bring Lifeward towards profitability Lifeward's FDA-approved ReWalk® and AlterG® products generated $26 million in last four quarters NEW YORK, Jan. 13, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ("Oramed") and Lifeward Ltd. (NASDAQ: LFWD) ("Lifeward") today announced the signing of binding agreements for a strategic transaction between Oramed, Lifeward and a certain accredited investor.

globenewswire.com

Lifeward Appoints Bob Marshall as Chairman of the Board

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, announced today that its Board of Directors has appointed Bob Marshall as Chairman of the Board, effective January 1, 2026. He replaces Joseph Turk, who will transition off the Board in connection with his new position at Fresenius Medical Care.

globenewswire.com

Lifeward Expands International Distribution of its ReWalk® Personal Robotic Exoskeleton into Mexico, Thailand, and the United Arab Emirates

Distribution agreement with Singapore-based Verita Neuro will provide patients the ReWalk Personal Exoskeleton as part of its multi-layered treatment modalities

globenewswire.com

Lifeward Broadens Reimbursement Coverage for ReWalk 7 Personal Robotic Exoskeleton as Humana Medicare Advantage Plan Issues Prior Authorization Approval

Humana and UnitedHealthcare, which granted authorization in November, are the two largest Medicare Advantage providers in the U.S., accounting for 47% of all Medicare Advantage enrollees This latest approval will help enhance timely access to cutting-edge personal exoskeleton solutions for individuals with spinal cord injury Reimbursement coverage is expected to give Lifeward stronger revenue and cash flow dynamics to scale growth MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.

globenewswire.com

UnitedHealthcare Medicare Advantage Plan Issues Prior Authorization Approval for a ReWalk 7 Personal Exoskeleton

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.

seekingalpha.com

Lifeward Ltd. (LFWD) Q3 2025 Earnings Call Transcript

Lifeward Ltd. ( LFWD ) Q3 2025 Earnings Call November 14, 2025 8:30 AM EST Company Participants Almog Adar - Chief Financial Officer William Grant - President, CEO & Director Conference Call Participants Yale Jen - Laidlaw & Company (UK) Ltd.

globenewswire.com

Lifeward Ltd. Reports Third Quarter 2025 Financial Results

Record quarter of ReWalk systems placed for Medicare beneficiaries since fee schedule established Ongoing efficiency initiatives drive 16% year-over-year decrease in quarterly cash burn and 27% decrease in quarterly Non-GAAP operating loss Entered into $3.0 million loan agreement with Oramed Ltd. providing additional capital support MARLBOROUGH, Mass.

globenewswire.com

Lifeward to Report Third Quarter Financial Results on November 14, 2025

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.

zacks.com

Lifeward Achieves European Approval for Latest ReWalk Exoskeleton

LFWD secures CE mark for its ReWalk 7 Personal Exoskeleton, unlocking new European sales potential with advanced features.

globenewswire.com

Lifeward Achieves CE Mark Approval for the ReWalk 7 Personal Exoskeleton

Seventh generation of industry-leading ReWalk Exoskeleton is now cleared for commercial launch in the European Union Seventh generation of industry-leading ReWalk Exoskeleton is now cleared for commercial launch in the European Union

seekingalpha.com

Lifeward Ltd. (LFWD) Q2 2025 Earnings Call Transcript

Lifeward Ltd. (NASDAQ:LFWD ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Almog Adar - Chief Financial Officer William Mark Grant - President, CEO & Director Conference Call Participants Benjamin Charles Haynor - Lake Street Capital Markets, LLC, Research Division I-Eh Jen - Laidlaw & Company (UK) Ltd.

zacks.com

Lifeward (LFWD) Reports Q2 Loss, Lags Revenue Estimates

Lifeward (LFWD) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.5 per share a year ago.

globenewswire.com

Lifeward Ltd. Reports Second Quarter 2025 Financial Results

Achieves r ecord n umber of ReWalk s ystems p laced f or Medicare b eneficiaries s ince fee schedule established Third consecutive quarter of U.S. ReWalk pipeline growth with over 130 qualified leads in process A ppoints n ew CEO and CFO to s pearhead s trategic c hange and a ccelerate g rowth MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.

globenewswire.com

Lifeward Names Almog Adar as New CFO, Strengthening Executive Leadership

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Almog Adar, who previously served as the Company's Vice President of Finance and Chief Accounting Officer, has been appointed as the Company's new Chief Financial Officer.

globenewswire.com

Lifeward to Report Second Quarter Financial Results on August 14, 2025

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its second quarter 2025 financial results before the markets open on Thursday, August 14, 2025.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance